Fluoroquinolones-resistant Shigella species in Iranian children:a meta-analysis

作     者：Farzad Khademi Amirhossein Sahebkar Farzad Khademi;Amirhossein Sahebkar

作者机构：Department of MicrobiologySchool of MedicineArdabil University of Medical SciencesDaneshgah StreetArdabil ***Iran Biotechnology Research CenterPharmaceutical Technology InstituteMashhad University of Medical SciencesMashhadIran Neurogenic Inflammation Research CenterMashhad University of Medical SciencesMashhadIran School of PharmacyMashhad University of Medical SciencesMashhadIran 

出 版 物：《World Journal of Pediatrics》 (世界儿科杂志（英文版）)

年 卷 期：2019年第15卷第5期

页      面：441-453页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100202[医学-儿科学] 10[医学] 

主　　题：Antibiotic resistance Fluoroquinolone Iran Shigella 

摘      要：Background Shigella is one of the most common causes of childhood dysentery along with high rate of morbidity and mortality in both developing and developed *** to the World Health Organization(WHO)reports,the prevalence of fluoroquinolones-resistant Shigella species is increasing worldwide which can cause treatment failure of Shigella *** there has not been any comprehensive information on drug-resistant Shigella species in Iran,we conducted the following meta-analysis to raise *** We conducted a literature search on antibiotic resistance of Shigella species to collect published studies in Iran using national and international *** search was performed by up to Jan 30,2019 and eligible studies were included in the meta-analysis by predefined *** Antimicrobial susceptibility testing using disk diffusion technique was the only used method in all included *** resistance characteristics of Shigella species against WHO recommended therapeutic regimens were as follows:*** 7%,*** 3.8%,*** 6.9%and *** 2.6%to ciprofloxacin,*** 27.9%,*** 19.3%,*** 15.7%and *** 9.5%to ceftriaxone and also *** 91.7%,*** 20.7%,*** 46.7%and *** 32.3%to *** to pivmecillinam has not been investigated in *** Our findings revealed that ciprofloxacin can still be used as the first-line antibiotic for Shigella infections in Iranian ***,it seems that second-line antibiotics i.e.,ceftriaxone and azithromycin are not good choices for treatment and thus not recommended.